The Senator Who Bet His Life on a Drug That Didn't Exist Two Years Ago
Former Senator Ben Sasse enrolled in a Revolution Medicines trial for a drug that scientists said couldn't exist, targeting the "undruggable" protein behind 90% of pancreatic cancers. The Phase 3 data that just dropped shows patients living nearly twice as long as those on chemo.
When Ben Sasse got his stage 4 pancreatic cancer diagnosis in December 2025, he faced a brutal reality. The five-year survival rate for metastatic pancreatic cancer sits below 5%. Median survival on standard chemotherapy hovers around 11 months if you're lucky. The disease kills more ruthlessly than almost any other cancer, and it moves fast.
So the former U.S. Senator from Nebraska did something unusual. He enrolled in a clinical trial for a drug that barely existed two years earlier, calling it his "best and only option." And the data that came out days ago suggests he might have made one of the smartest medical decisions of his life.
A Drug That Almost Nobody Thought Was Possible
To understand why this matters, you need to know about a protein called RAS. Think of RAS as a light switch inside your cells. When it works normally, it flips on to tell cells to grow, then flips off when the job is done. But in over 90% of pancreatic cancers, RAS gets stuck in the "on" position. The cells never stop dividing.
For decades, scientists called RAS "undruggable." The protein is tiny, smooth, and offers almost nowhere for a drug molecule to grab hold. It was like trying to put a clamp on a greased marble. A few years ago, researchers cracked one specific RAS mutation (called G12C) in lung cancer, but pancreatic cancer mostly harbors different RAS mutations. Those remained untouchable.
Revolution Medicines took a completely different approach. Their drug, daraxonrasib, works like a molecular glue. Instead of trying to block RAS directly, it sticks RAS to another protein called cyclophilin A. Imagine gluing a basketball to someone's hand right before they try to pass it; the ball never reaches the next player. In this case, the "pass" is the signal telling cancer cells to keep growing. Daraxonrasib intercepts it.
The critical innovation: it targets RAS in its active, "on" state. Earlier drugs could only grab RAS when it was switched off, which made them useless against the mutations that dominate pancreatic cancer. Revolution's drug doesn't care which specific mutation is jamming the switch. It works across multiple variants.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Trial That Ended Early (In a Good Way)
On April 13, 2026, Revolution Medicines dropped results from its Phase 3 trial, called RASolute 302. The trial tested daraxonrasib against standard chemotherapy in patients with metastatic pancreatic cancer who had already tried other treatments.
The numbers were striking. Patients on daraxonrasib lived a median of 13.2 months, compared to 6.7 months on chemo. That's nearly double. The drug cut the risk of death by 60%, with a p-value below 0.0001 (translation: the odds this happened by random chance are essentially zero).
The results were so strong that the trial's independent monitoring board determined at a planned interim analysis that all endpoints could be considered final.
This wasn't just a progression-free survival improvement, which measures how long until tumors start growing again. This was overall survival, the gold standard. Patients actually lived longer, not just scanned better.
Sasse's Gamble
Ben Sasse isn't your typical clinical trial patient, at least not in terms of public profile. The Yale-educated historian served in the U.S. Senate from 2015 to 2023 before becoming president of the University of Florida. He stepped down from that role in 2024 to care for his wife, Melissa, after her epilepsy diagnosis. Then his own health crisis arrived.
His enrollment isn't in the Phase 3 trial that generated these headline numbers. Sasse joined an earlier-phase trial testing daraxonrasib as a first-line therapy, meaning it's the first treatment given after diagnosis rather than a backup plan after chemo fails. Early data from that setting suggest the benefits could be even greater when the drug is used upfront, before the cancer has weathered previous treatments and evolved resistance.
Sasse has been candid about the experience. He called daraxonrasib a "nasty" drug that causes "crazy stuff" like bleeding and rash. Revolution Medicines maintains the side effect profile is manageable with no new safety signals, but Sasse's honesty is refreshing. Clinical trials aren't spa days. The question is always whether the trade-off is worth it.
By his own account, the answer is yes. Sasse has credited the trial with extending both the quantity and quality of his life.
Why Pancreatic Cancer Is Biotech's Toughest Opponent
Pancreatic cancer is the disease that makes oncologists lose sleep. It's the only major cancer with a five-year survival rate below 20% across all stages. For context: the overall five-year survival rate is roughly 13%. If it's caught early enough for surgery (and only 15-20% of patients qualify), that number climbs to maybe 30-40%. But most people aren't that fortunate.
The standard first-line treatment for metastatic disease is a chemotherapy cocktail called FOLFIRINOX or a combination of gemcitabine and nab-paclitaxel. These regimens can extend median survival to around 11 or 12 months, but the side effects are punishing and long-term remissions are exceedingly rare.
What makes daraxonrasib's 13.2-month result so remarkable is that it was achieved in second-line patients, people whose cancers had already progressed through initial treatment. Matching or beating first-line chemo results in a second-line setting is like a relief pitcher throwing a no-hitter after the starter got shelled for six innings.
And there's a frontline trial already underway. RASolute 303 is testing daraxonrasib alone and in combination with chemo for untreated metastatic pancreatic cancer patients. If first-line results mirror or exceed the second-line data, this could reshape how doctors approach the disease from day one.
Wall Street Noticed
Revolution Medicines' stock (ticker: RVMD) surged 41% on the day the data dropped, jumping from about $96 to around $135. By mid-April, shares were trading in the $136-$147 range. The company had been hovering in the low $90s just weeks earlier.
Analysts scrambled to update their models. Evercore ISI slapped a $200 price target on the stock. Stifel went to $170; Wells Fargo landed at $167.
The AACR Annual Meeting (April 17-22 in San Diego) looms as the next catalyst. Revolution has nine presentations scheduled there. Data from the Phase 3 trial are expected at the ASCO Annual Meeting in late May.
Perhaps most importantly, the company received a Commissioner's National Priority Voucher from the FDA back in October 2025. That could compress the typical review timeline to just one or two months after submission. If Revolution files soon, approval could come remarkably fast.
The Bigger Picture: A Former Senator Puts a Face on the Data
Clinical trial results are abstractions until someone puts a human face on them. When a former U.S. Senator publicly enrolls in a trial and talks openly about bleeding, rashes, and the brutal calculus of choosing an experimental drug over conventional comfort, it does something that a p-value never can: it makes people pay attention.
Sasse's visibility could accelerate enrollment in Revolution's ongoing trials. Pancreatic cancer trials have historically struggled to recruit patients quickly enough, partly because the disease progresses so fast and partly because awareness of experimental options remains low. A public figure saying "this is my best and only option" carries weight that no billboard or website can match.
There's a tension here, of course. Celebrity endorsements of specific treatments can create unrealistic expectations. Not everyone will respond the way the median patient in a trial does; that's what "median" means. And early-phase trials, like the one Sasse is in, carry more uncertainty than a completed Phase 3 study.
But the broader signal is hard to ignore. For the first time, a drug has nearly doubled survival in second-line pancreatic cancer with a once-daily pill. The "undruggable" target has been drugged. And a man who spent years debating policy in the Senate is now, by his own choice, a data point in a trial that could change how we treat one of the deadliest cancers on Earth.
The next few months will tell us whether that bet pays off for everyone, not just the patients lucky enough to get in early.
Deals & M&A4 min read
The App That Treats Schizophrenia Just Lost 27% of Its Team
Click Therapeutics raised $50 million and then cut 27% of its staff in the same week. The company is betting it can succeed where Pear Therapeutics spectacularly failed: turning a prescription app into a real commercial product.
